11 – 20 of 98
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Levodopa Dose Equivalency in Parkinson's Disease : Updated Systematic Review and Proposals
(
- Contribution to journal › Article
-
Mark
The Impact of COVID-19 on Parkinson's Disease : A Case-Controlled Registry and Questionnaire Study on Clinical Markers and Patients' Perceptions
(
- Contribution to journal › Article
-
Mark
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
(
- Contribution to journal › Article
-
Mark
Tumoral parkinsonism—Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment
(
- Contribution to journal › Scientific review
-
Mark
Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease : clinical and therapeutic considerations
(
- Contribution to journal › Scientific review
-
Mark
Healthcare resource utilization and device-aided therapy discussions with eligible patients across the Parkinson's disease continuum : Revelations from the MANAGE-PD validation cohort
(
- Contribution to journal › Article
-
Mark
A Paradigm Shift in the Management of Patients with Parkinson's Disease
(
- Contribution to journal › Scientific review
-
Mark
Dopamine agonist serum concentrations and impulse control disorders in Parkinson's disease
2023) In European Journal of Neurology(
- Contribution to journal › Article
-
Mark
A systematic practice review : Providing palliative care for people with Parkinson’s disease and their caregivers
2023) In Palliative Medicine(
- Contribution to journal › Scientific review
- 2022
-
Mark
Does the 5–2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5–2-1-positive patients in 7 countries
(
- Contribution to journal › Article